Clinical aspects of Marburg hemorrhagic fever

Future Virology

Volumn 6, Issue 9, 2011, Pages 1091-1106

  Mehedi, Masfique ^a,b   Groseth, Allison ^b   Feldmann, Heinz ^a,b   Ebihara, Hideki ^b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

diagnosis; disease; hemorrhagic fever; Marburg virus; pathogenesis; pathology; prevention; treatment

Indexed keywords

ANTIBIOTIC AGENT; ANTIPYRETIC AGENT; BLOOD CLOTTING FACTOR; DEFEROXAMINE MESYLATE; HEPARIN; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; RIBAVIRIN; TUMOR NECROSIS FACTOR ALPHA;

BACTERIAL INFECTION; CHLOROCEBUS; DISEASE COURSE; DISSEMINATED INTRAVASCULAR CLOTTING; EBOLA HEMORRHAGIC FEVER; EPIDEMIC; FEVER; HEMODIALYSIS; HUMAN; IMMUNITY; INFLUENZA; INTENSIVE CARE; KIDNEY FAILURE; LABORATORY DIAGNOSIS; MARBURG HEMORRHAGIC FEVER; MARBURG VIRUS; MORTALITY; NONHUMAN; PATHOGENESIS; PHARYNGITIS; PRIORITY JOURNAL; RASH; REVIEW; THROMBOCYTOPENIA; VIRUS TRANSMISSION;

FILOVIRIDAE; LAKE VICTORIA MARBURGVIRUS; MARBURGVIRUS; PRIMATES;

EID: 80052986238     PISSN: 17460794     EISSN: 17460808     Source Type: Journal    
DOI: 10.2217/fvl.11.79     Document Type: Review

References (108)

1. Towner JS, Khristova ML, Sealy TK, et al. Marburg virus genomics and association with a large hemorrhagic fever outbreak in Angola. J. Virol. 80(13), 6497-6516 (2006) (Pubitemid 43927452)
2. Sanchez A, Geisbert T, Feldmann H. Filoviridae - Marburg and ebola viruses. In:Fields Virology. Knipe D (Ed.). Lippincott Williams and Wilkins, PA, USA, 1410-1448 (2007)
3. Martini GA. Marburg virus disease. Clinical syndrome. In:Marburg Virus Disease. Martini GA, Siegert R (Eds). Springer-Verlag, NY, USA, 1-9 (1971)
4. Henderson BE, Kissling RE, Williams MC, Kafuko GW, Martin M. Epidemiological studies in Uganda relating to the 'Marburg' agent. In:Marburg Virus Disease. Martini GA, Siegert R (Eds). Springer-Verlag, NY, USA, 166-176 (1971)
5. Martini GA, Knauff HG, Schmidt HA, Mayer G, Baltzer G. [On the hitherto unknown, in monkeys originating infectious disease: Marburg virus disease]. Dtsch Med. Wochenschr. 93(12), 559-571 (1968)
6. Conrad JL, Isaacson M, Smith EB, et al. Epidemiologic investigation of Marburg virus disease, Southern Africa, 1975. Am. J. Trop. Med. Hyg. 27(6), 1210-1215 (1978) (Pubitemid 9080442)
7. Peterson AT, Lash RR, Carroll DS, Johnson KM. Geographic potential for outbreaks of Marburg hemorrhagic fever. Am. J. Trop. Med. Hyg. 75(1), 9-15 (2006) (Pubitemid 351627562)
8. Bausch DG, Nichol ST, Muyembe-Tamfum JJ, et al. Marburg hemorrhagic fever associated with multiple genetic lineages of virus. N. Engl. J. Med. 355(9), 909-919 (2006) (Pubitemid 44315983)
9. CDC: Imported case of Marburg hemorrhagic fever - Colorado, 2008. MMWR Morb. Mortal. Wkly Rep. 58(49), 1377-1381 (2009)
10. Timen A, Koopmans MP, Vossen AC, et al. Response to imported case of Marburg hemorrhagic fever, The Netherland. Emerg. Infect. Dis. 15(8), 1171-1175 (2009)
11. Falzarano D, Feldmann H. Marburg virus. In:Encyclopedia of Virology . Mahy BWJ, van Regenmortel MHV (Eds). Elsevier, UK, 272-280 (2008)
12. Nikiforov VV, Turovskii Iu I, Kalinin PP, et al. [A case of a laboratory infection with Marburg fever]. Zh. Mikrobiol. Epidemiol. Immunobiol. (3), 104-106 (1994)
13. Ignatyev GM, Streltsova MA, Kashentseva EA, Patrushev NA, Ginko SI, Agafonov AP. Immunity indexes in the personnel involved in haemorrhagic virus investigation. In:Proceedings of the 1996 ERDEC Scientific Conference on Chemical and Biological Defense Research. Berg DA (Ed.). Aberdeen Proving Ground, MD, USA, 323-330 (1997)
14. Hennessen W. Epidemiology of 'Marburg virus' disease. In:Marburg Virus Disease. Martini GA, Siegert R (Eds). Springer-Verlag, NY, USA, 159-165 (1971)
15. Gear JS, Cassel GA, Gear AJ, et al. Outbreak of Marburg virus disease in Johannesburg. BMJ 4(5995), 489-493 (1975)
16. Borchert M, Muyembe-Tamfum JJ, Colebunders R, Libande M, Sabue M, Van Der Stuyft P. Short communication: a cluster of Marburg virus disease involving an infant. Trop. Med. Int. Health 7(10), 902-906 (2002) (Pubitemid 35205377)
17. Bausch DG, Borchert M, Grein T, et al. Risk factors for Marburg hemorrhagic fever, Democratic Republic of the Congo. Emerg. Infect. Dis. 9(12), 1531-1537 (2003) (Pubitemid 37505446)
18. Martini GA, Schmidt HA. [Spermatogenic transmission of the 'Marburg virus'. (Causes of 'Marburg simian disease')]. Klin. Wochenschr. 46(7), 398-400 (1968)
19. Lub M, Sergeev AN, Piankov OV, Piankova OG, Petrishchenko VA, Kotliarov LA. [Certain pathogenetic characteristics of a disease in monkeys in infected with the Marburg virus by an airborne route]. Vopr. Virusol. 40(4), 158-161 (1995) (Pubitemid 26101753)
20. Alves DA, Glynn AR, Steele KE, et al. Aerosol exposure to the angola strain of Marburg virus causes lethal viral hemorrhagic fever in cynomolgus macaques. Vet. Pathol. 47(5), 831-851 (2010)
21. Towner JS, Amman BR, Sealy TK, et al. Isolation of genetically diverse Marburg viruses from Egyptian fruit bats. PLoS Pathog. 5(7), E1000536 (2009)
22. Slenczka WG. The Marburg virus outbreak of 1967 and subsequent episodes. Curr. Top. Microbiol. Immunol. 235, 49-75 (1999) (Pubitemid 28500195)
23. Geisbert TW, Geisbert JB, Leung A, et al. Single injection vaccine protects nonhuman primates against Marburg virus and three species of ebola virus. J. Virol. 7296-7304 (2009)
24. Geisbert TW, Daddario-DiCaprio KM, Geisbert JB, et al. Marburg virus Angola infection of rhesus macaques: pathogenesis and treatment with recombinant nematode anticoagulant protein c2. J. Infect. Dis. 196(Suppl. 2), S372-S381 (2007) (Pubitemid 351417284)
25. Colebunders R, Tshomba A, Van Kerkhove MD, et al. Marburg hemorrhagic fever in Durba and Watsa, Democratic Republic of the Congo: clinical documentation, features of illness, and treatment. J. Infect. Dis. 196(Suppl. 2), S148-S153 (2007) (Pubitemid 351417254)
26. Stille W, Boehle E. Clinical course and prognosis of Marburg virus ('green-monkey') disease. In:Marburg Virus Disease. Martini GA, Siegert R (Eds). Springer-Verlag, NY, USA, 10-18 (1971)
27. Bente D, Gren J, Strong JE, Feldmann H. Disease modeling for Ebola and Marburg viruses. Dis. Model Mech. 2(1-2), 12-17 (2009)
28. Spiridonov VA, Bazhutin NB, Belanov EF, et al. [Changes in the blood serum aminotransferase activity in the experimental infection of Cercopithecus aethiops monkeys with the Marburg virus]. Vopr. Virusol. 37(3), 156-157 (1992) (Pubitemid 23268540)
29. Simpson DI. Marburg agent disease: in monkeys. Trans. R. Soc. Trop. Med. Hyg. 63(3), 303-309 (1969)
30. Simpson DI, Zlotnik I, Rutter DA. Vervet monkey disease. Experiment infection of guinea pigs and monkeys with the causative agent. Br. J. Exp. Pathol. 49(5), 458-464 (1968)
31. Johnson ED, Johnson BK, Silverstein D, et al. Characterization of a new Marburg virus isolated from a 1987 fatal case in Kenya. Arch. Virol. Suppl. 11, 101-114 (1996) (Pubitemid 126446184)
32. Gonchar NI, Pshenichnov VA, Pokhodiaev VA, Lopatov KL, Firsova IV. [The sensitivity of different experimental animals to the Marburg virus]. Vopr. Virusol. 36(5), 435-437 (1991)
33. Daddario-DiCaprio KM, Geisbert TW, Geisbert JB, et al. Cross-protection against Marburg virus strains by using a live, attenuated recombinant vaccine. J. Virol. 80(19), 9659-9666 (2006) (Pubitemid 44435640)
34. Daddario-DiCaprio KM, Geisbert TW, Stroher U, et al. Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: an efficacy assessment. Lancet 367(9520), 1399-1404 (2006)
35. Bausch DG, Geisbert TW. Development of vaccines for Marburg hemorrhagic fever. Expert Rev. Vaccines 6(1), 57-74 (2007) (Pubitemid 46237547)
36. Hass R, Maass G. Experimental infection of monkeys with the Marburg virus. In:Marburg Virus Disease. Martini GA, Siegert R (Eds). Springer-Verlag, NY, USA, 136-143 (1971)
37. Hevey M, Negley D, Geisbert J, Jahrling P, Schmaljohn A. Antigenicity and vaccine potential of Marburg virus glycoprotein expressed by baculovirus recombinants. Virology 239(1), 206-216 (1997) (Pubitemid 28027084)
38. Warfield KL, Alves DA, Bradfute SB, et al. Development of a model for Marburg virus based on severe-combined immunodeficiency mice. Virol. J. 4, 108 (2007)
39. Warfield KL, Bradfute SB, Wells J, et al. Development and characterization of a mouse model for Marburg hemorrhagic fever. J. Virol. 83(13), 6404-6415 (2009)
40. Robin Y, Bres P, Camain R. Passage of Marburg virus in guinea pigs. In:Marburg Virus Disease. Martini GA, Siegert R (Eds). Springer-Verlag, NY, USA, 115-122 (1971)
41. Zlotnik I. Marburg agent disease: pathology. Trans. R. Soc. Trop. Med. Hyg. 63(3), 310-327 (1969)
42. Zlotnik I, Simpson DI. The pathology of experimental vervet monkey disease in hamsters. Br. J. Exp. Pathol. 50(4), 393-399 (1969)
43. Geisbert TW, Jaax NK. Marburg hemorrhagic fever: report of a case studied by immunohistochemistry and electron microscopy. Ultrastruct. Pathol. 22(1), 3-17 (1998) (Pubitemid 28103807)
44. Fritz EA, Geisbert JB, Geisbert TW, Hensley LE, Reed DS. Cellular immune response to Marburg virus infection in cynomolgus macaques. Viral. Immunol. 21(3), 355-363 (2008)
45. Stroher U, West E, Bugany H, Klenk HD, Schnittler HJ, Feldmann H. Infection and activation of monocytes by Marburg and ebola viruses. J. Virol. 75(22), 11025-11033 (2001) (Pubitemid 33031570)
46. Feldmann H, Bugany H, Mahner F, Klenk HD, Drenckhahn D, Schnittler HJ. Filovirus-induced endothelial leakage triggered by infected monocytes/ macrophages. J. Virol. 70(4), 2208-2214 (1996) (Pubitemid 26087581)
47. Marty AM, Jahrling PB, Geisbert TW. Viral hemorrhagic fevers. Clin. Lab. Med. 26(2), 345-386, VIII (2006) (Pubitemid 43947403)
48. Zlotnik I. 'Marburg disease'. The pathology of experimentally infected hamsters. In:Marburg Virus Disease. Martini GA, Siegert R (Eds). Springer-Verlag, NY, USA, 129-135 (1971)
49. Geisbert TW, Hensley LE, Gibb TR, Steele KE, Jaax NK, Jahrling PB. Apoptosis induced in vitro and in vivo during infection by ebola and Marburg viruses. Lab. Invest. 80(2), 171-186 (2000) (Pubitemid 30120970)
50. Bechtelsheimer J, Korb G, Gedigk P. Marburg virus hepatitis. In:Marburg Virus Disease. Martini GA, Siegert R (Eds). Springer-Verlag, NY, USA, 62-67 (1971)
51. Becker S, Spiess M, Klenk HD. The asialoglycoprotein receptor is a potential liver-specific receptor for Marburg virus. J. Gen. Virol. 76(Pt 2), 393-399 (1995)
52. Havemann K, Schmidt HA. Marburg virus disease. In:Marburg Virus Disease. Martini GA, Siegert R (Eds). Springer-Verlag, NY, USA, 34-40 (1971)
53. Gedigk P, Bechtelsheimer H, Korb G. Pathologic anatomy of the Marburg virus disease. In:Marburg Virus Disease. Martini GA, Siegert R (Eds). Springer-Verlag, NY, USA, 50-54 (1971)
54. Egbring R, Slenczka W, Baltzer G. Clincal manifestations and mechanism of the haemorrhagic diathesis in Marburg virus disease. In:Marburg Virus Disease. Martini GA, Siegert R (Eds). Springer-Verlag, NY, USA, 41-49 (1971)
55. Gedigk P, Bechtelsheimer H, Korb G. [Pathological anatomy of the 'Marburg virus' disease (the so-called 'Marburg monkey disease')]. Dtsch Med. Wochenschr. 93(12), 590-601 (1968)
56. Geisbert TW, Young HA, Jahrling PB, et al. Mechanisms underlying coagulation abnormalities in ebola hemorrhagic fever: overexpression of tissue factor in primate monocytes/macrophages is a key event. J. Infect. Dis. 188(11), 1618-1629 (2003) (Pubitemid 38010671)
57. Geisbert TW, Hensley LE, Jahrling PB, et al. Treatment of ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys. Lancet 362(9400), 1953-1958 (2003) (Pubitemid 37548417)
58. Gupta M, Spiropoulou C, Rollin PE. Ebola virus infection of human PBMCs causes massive death of macrophages, CD4 and CD8 T cell sub-populations in vitro. Virology 364(1), 45-54 (2007) (Pubitemid 46839124)
59. Hensley LE, Young HA, Jahrling PB, Geisbert TW. Proinflammatory response during ebola virus infection of primate models: possible involvement of the tumor necrosis factor receptor superfamily. Immunol. Lett. 80(3), 169-179 (2002) (Pubitemid 34136004)
60. Bray M. Filoviruses. In:Clinical Virology (3rd Edition). Richman DD, Whitley RJ, Hayden FG (Eds). American Society of Microbiology, Washington, DC, USA, 923-941 (2009)
61. Yaddanapudi K, Palacios G, Towner JS, et al. Implication of a retrovirus-like glycoprotein peptide in the immunopathogenesis of ebola and Marburg viruses. FASEB J. 20(14), 2519-2530 (2006) (Pubitemid 44953824)
62. Basler CF, Mikulasova A, Martinez-Sobrido L, et al. The ebola virus VP35 protein inhibits activation of interferon regulatory factor 3. J. Virol. 77(14), 7945-7956 (2003) (Pubitemid 36792791)
63. Cardenas WB, Loo YM, Gale M Jr, et al. Ebola virus VP35 protein binds double-stranded RNA and inhibits a/b interferon production induced by RIG-I signaling. J. Virol. 80(11), 5168-5178 (2006)
64. Reid SP, Leung LW, Hartman AL, et al. Ebola virus VP24 binds karyopherin a 1 and blocks STAT1 nuclear accumulation. J. Virol. 80(11), 5156-5167 (2006)
65. Valmas C, Grosch MN, Schumann M, et al. Marburg virus evades interferon responses by a mechanism distinct from ebola virus. PLoS Pathog. 6(1), E1000721 (2010)
66. Grolla A, Lucht A, Dick D, Strong JE, Feldmann H. Laboratory diagnosis of ebola and Marburg hemorrhagic fever. Bull. Soc. Path. Exot. 98(3), 205-209 (2005) (Pubitemid 41500861)
67. Grolla A, Jones SM, Fernando L, et al. The use of a mobile laboratory unit in support of patient management and epidemiological surveillance during the 2005 Marburg outbreak in Angola. PLoS Negl. Trop. Dis. 5(5), E1183 (2011)
68. Towner JS, Sealy TK, Ksiazek TG, Nichol ST. High-throughput molecular detection of hemorrhagic fever virus threats with applications for outbreak settings. J. Infect. Dis. 196(Suppl. 2), S205-S212 (2007) (Pubitemid 351417262)
69. Drosten C, Gottig S, Schilling S, et al. Rapid detection and quantification of RNA of ebola and Marburg viruses, Lassa virus, Crimean- Congo hemorrhagic fever virus, rift valley fever virus, dengue virus, and yellow fever virus by real-time reverse transcription-PCR. J. Clin. Microbiol. 40(7), 2323-2330 (2002) (Pubitemid 34747327)
70. Kurosaki Y, Grolla A, Fukuma A, Feldmann H, Yasuda J. Development and evaluation of a simple assay for Marburg virus detection using a reverse transcription-loop-mediated isothermal amplification method. J. Clin. Microbiol. 48(7), 2330-2336 (2010)
71. Weidmann M, Muhlberger E, Hufert FT. Rapid detection protocol for filoviruses. J. Clin. Virol. 30(1), 94-99 (2004) (Pubitemid 38457075)
72. Ogawa H, Miyamoto H, Ebihara H, et al. Detection of all known filovirus species by reverse transcription-polymerase chain reaction using a primer set specific for the viral nucleoprotein gene. J. Virol. Methods 171(1), 310-313 (2011)
73. Saijo M, Georges-Courbot MC, Fukushi S, et al. Marburgvirus nucleoprotein-capture enzyme-linked immunosorbent assay using monoclonal antibodies to recombinant nucleoprotein: detection of authentic Marburg virus. Jpn J. Infect. Dis. 59(5), 323-325 (2006) (Pubitemid 44650378)
74. Nakayama E, Yokoyama A, Miyamoto H, et al. Enzyme-linked immunosorbent assay for detection of filovirus species-specific antibodies. Clin. Vaccine Immunol. 17(11), 1723-1728 (2010)
75. Saijo M, Niikura M, Morikawa S, et al. Enzyme-linked immunosorbent assays for detection of antibodies to ebola and Marburg viruses using recombinant nucleoproteins. J. Clin. Microbiol. 39(1), 1-7 (2001) (Pubitemid 32059559)
76. Sherwood LJ, Osborn LE, Carrion R Jr, Patterson JL, Hayhurst A. Rapid assembly of sensitive antigen-capture assays for Marburg virus, using in vitro selection of llama single-domain antibodies, at biosafety level 4. J. Infect. Dis. 196(Suppl. 2), S213-S219 (2007) (Pubitemid 351417263)
77. Palacios G, Quan PL, Jabado OJ, et al. Panmicrobial oligonucleotide array for diagnosis of infectious diseases. Emerg. Infect. Dis. 13(1), 73-81 (2007) (Pubitemid 46057840)
78. Jeffs B. A clinical guide to viral haemorrhagic fevers: ebola, Marburg and Lassa. Trop. Doct. 36(1), 1-4 (2006) (Pubitemid 43242221)
79. Martini GA. Marburg agent disease: in man. Trans. R. Soc. Trop. Med. Hyg. 63(3), 295-302 (1969)
80. Todorovitch K, Mocitch M, Klasnja R. Clinical picture of two patients infected by the Marburg vervet virus. In:Marburg Virus Disease. Martini GA, Siegert R (Eds). Springer-Verlag, NY, USA, 19-23 (1971)
81. Snell NJ. Ribavirin-current status of a broad spectrum antiviral agent. Expert Opin. Pharmacol. 2(8), 1317-1324 (2001) (Pubitemid 32750371)
82. Ignatiev GM, Strelitsova MA, Agafonov AP, Kashentseva EA, Prozorovskii NS. [Experimental study of possible treatment of Marburg hemorrhagic fever with Desferal, ribavirin, and homologous interferon]. Vopr. Virusol. 41(5), 206-209 (1996)
83. Kolokolitsov AA, Davidovich IA, Strelitsova MA, Nesterov AE, Agafonova OA, Agafonov AP. The use of interferon for emergency prophylaxis of Marburg hemorrhagic fever in monkeys. Bull. Exp. Biol. Med. 132(1), 686-688 (2001) (Pubitemid 34071135)
84. Borisevich IV, Potryvaeva NV, Melinikov SA, Evseev AA, Krasnianskii VP, Maksimov VA. [Design of equine serum-based Marburg virus immunoglobulin]. Vopr. Virusol. 53(1), 39-41 (2008) (Pubitemid 351334117)
85. Dye JM. Post-exposure transfer of immunoglobulin G from convalescent survivors protects rhesus macaques from Marburg virus. Presented at: 5th International Symposium on Filoviruses. Tokyo, Japan, 19-21 April 2010
86. Razumov IA, Belanov EF, Bormotov NI, Kazachinskaia EI. [Detection of antiviral activity of monoclonal antibodies, specific to Marburg virus proteins]. Vopr. Virusol. 46(1), 33-37 (2001) (Pubitemid 33758246)
87. Hevey M, Negley D, Schmaljohn A. Characterization of monoclonal antibodies to Marburg virus (strain Musoke) glycoprotein and identification of two protective epitopes. Virology 314(1), 350-357 (2003) (Pubitemid 37153323)
88. Warren TK, Warfield KL, Wells J, et al. Advanced antisense therapies for postexposure protection against lethal filovirus infections. Nat. Med. 16(9), 991-994 (2010)
89. Garbutt M, Liebscher R, Wahl-Jensen V, et al. Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses. J. Virol. 78(10), 5458-5465 (2004) (Pubitemid 38581495)
90. Geisbert TW, Hensley LE, Geisbert JB, et al. Postexposure treatment of Marburg virus infection. Emerg. Infect. Dis. 16(7), 1119-1122 (2010)
91. Ignatiev GM, Bukin EK, Otrashevskaia EV. [An experimental study of possibility of treatment of hemorrhagic fever Marburg by Remicade]. Vestn. Ross. Akad. Med. Nauk. (11), 22-24 (2004) (Pubitemid 39611242)
92. Ignatiev GM, Strelitsova MA, Kashentseva EA, Patrushev NA. [Effects of tumor necrosis factor antiserum of the course of Marburg hemorrhagic fever]. Vestn. Ross. Akad. Med. Nauk. (3), 35-38 (1998)
93. Ignatyev G, Steinkasserer A, Streltsova M, Atrasheuskaya A, Agafonov A, Lubitz W. Experimental study on the possibility of treatment of some hemorrhagic fevers. J. Biotechnol. 83(1-2), 67-76 (2000)
94. Ignatyev GM. Immune response to filovirus infections. Curr. Top. Microbiol. Immunol. 235, 205-217 (1999) (Pubitemid 28500201)
95. Riemenschneider J, Garrison A, Geisbert J, et al. Comparison of individual and combination DNA vaccines for B. anthracis, ebola virus, Marburg virus and Venezuelan equine encephalitis virus. Vaccine 21(25-26), 4071-4080 (2003) (Pubitemid 37345136)
96. Geisbert TW, Bailey M, Geisbert JB, et al. Vector choice determines immunogenicity and potency of genetic vaccines against Angola Marburg virus in nonhuman primates. J. Virol. 84(19), 10386-10394 (2010)
97. Geisbert TW, Bausch DG, Feldmann H. Prospects for immunisation against Marburg and ebola viruses. Rev. Med. Virol. 20(6), 344-357 (2010)
98. Jones SM, Feldmann H, Stroher U, et al. Live attenuated recombinant vaccine protects nonhuman primates against ebola and Marburg viruses. Nat. Med. 11(7), 786-790 (2005) (Pubitemid 41021212)
99. Geisbert TW, Daddario-Dicaprio KM, Geisbert JB, et al. Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with ebola and Marburg viruses. Vaccine 26(52), 6894-6900 (2008)
100. Hevey M, Negley D, Staley A, Schmaljohn A. Determination of vaccine components required for protecting cynomologous macaques against genotypically divergent isolates of Marburg virus. Presentedat: 20th Annual Meeting of the American Society for Virology. Madison, WI, USA, 21-25 July 2001
101. Swenson DL, Warfield KL, Larsen T, Alves DA, Coberley SS, Bavari S. Monovalent virus-like particle vaccine protects guinea pigs and nonhuman primates against infection with multiple Marburg viruses. Expert Rev. Vaccines 7(4), 417-429 (2008) (Pubitemid 351656813)
102. Feldmann H. Marburg hemorrhagic fever - the forgotten cousin strikes. N. Engl. J. Med. 355(9), 866-869 (2006) (Pubitemid 44315978)
103. Smith DH, Johnson BK, Isaacson M, et al. Marburg-virus disease in Kenya. Lancet 1(8276), 816-820 (1982) (Pubitemid 12133655)
104. Stille W, Bohle E, Helm E, van Rey W, Siede W. [On an infectious disease transmitted by cercopithecus aethiops. ("green monkey disease")]. Dtsch Med. Wochenschr. 93(12), 572-582 (1968)
105. Sergeev AN, Ryzhikov AB, Bulychev LE, et al. [Study of the treatment-prophylactic effect of immunomodulators in experimental infections, caused by Marburg, ebola, and Venezuelan equine encephalitis viruses]. Vopr. Virusol. 42(5), 226-229 (1997) (Pubitemid 127519788)
106. Warren TK, Warfield KL, Wells J, et al. Antiviral activity of a small-molecule inhibitor of filovirus infection. Antimicrob. Agents Chemother. 54(5), 2152-2159 (2010)
107. Hevey M, Negley D, Pushko P, Smith J, Schmaljohn A. Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates. Virology 251(1), 28-37 (1998) (Pubitemid 28527716)
108. Swenson DL, Wang D, Luo M, et al. Vaccine to confer to nonhuman primates complete protection against multistrain Ebola and Marburg virus infections. Clin. Vaccine Immunol. 15(3), 460-467 (2008) (Pubitemid 351967082)